Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression
Article first published online: 20 DEC 2012
Copyright © 2012 John Wiley & Sons, Ltd.
International Journal of Geriatric Psychiatry
Volume 28, Issue 9, pages 925–932, September 2013
How to Cite
Jamerson, B. D., Payne, M. E., Garrett, M. E., Ashley-Koch, A. E., Speer, M. C. and Steffens, D. C. (2013), Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression. Int. J. Geriat. Psychiatry, 28: 925–932. doi: 10.1002/gps.3899
- Issue published online: 5 AUG 2013
- Article first published online: 20 DEC 2012
- Manuscript Accepted: 10 OCT 2012
- Manuscript Received: 8 JUN 2012
- late-life depression;
- depressive disorder/genetics;
- single nucleotide polymorphisms;
The primary aims of this study were to (i) determine whether folate metabolism genetic polymorphisms predict age of onset and occurrence of late life depression; and (ii) determine whether folate metabolism genetic polymorphisms predict response to antidepressant medications in late-life depression.
This study used the Conte Center for the Neuroscience of Depression and the Neurocognitive Outcomes of Depression in the Elderly Study database, which includes individuals aged ≥60. The folate nutrition assessment was determined by the Block Food Frequency Questionnaire. Genotype was evaluated for 15 single nucleotide polymorphisms from 10 folate metabolism genes. Logistic regression models were used to examine genetic polymorphisms and folate estimates with association with depression age of onset and remission status.
There were 304 Caucasians in the database, 106 of these were not depressed and 198 had a diagnosis of depression. There were no significant differences between remitters and non-remitters in age, sex or estimated folate intakes. There were no folate estimates or folate metabolism gene single nucleotide polymorphisms that significantly predicted age of onset of depression or occurrence of depression. Methionine synthase reductase (MTRR) A66G (rs1801394) was significantly associated with remission status (p = 0.0077) such that those with the AA genotype were 3.2 times as likely as those with the GG genotype to be in remission (p = 0.0020). Methylenetetrahydrofolate reductase A1298C (rs1801131) achieved a borderline significance for association with remission status (p = 0.0313).
The major finding from this study is that the MTRR A66G genotype predicts response to selective serotonin reuptake inhibitor antidepressants in late life depression. Copyright © 2012 John Wiley & Sons, Ltd.